Appareil pulmonaire TET-SEL A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy. Paris NICOLAS GIRARD
Appareil Digestif SCARCE (C17-02 PRODIGE 60) A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma Paris
Sein Néoadjuvant ALIENOR Detection of Circulating Tumoral DNA Mutations (Sequential Assessment) Following Neoadjuvant Chemotherapy for Breast Cancer: Clinical Validity (ALIENOR Study) Paris, Saint-Cloud
Recherches "plusieurs pathologies" CIRCA-HPV (IC 2017-01) Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses. Paris, Saint-Cloud BRUNO BUECHER
Recherches "plusieurs pathologies" NIPINEC (GCO-001) A GCO Trial Exploring the Efficacy and Safety of Nivolumab Monotherapy or Nivolumab Plus Ipilimumab in Pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) Paris NICOLAS GIRARD
Appareil pulmonaire CheckMate 592 (CA209-592) Protocol Title: An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC). Paris NICOLAS GIRARD
Sein métastatique RH+ XENERA-1 (BI 1280-0022) A multi-centre, double-blind, placebo-controlled,randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease Paris
Recherches "plusieurs pathologies" CA209-848 A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Paris EMANUELA ROMANO
Appareil pulmonaire ENTREE-LUNG (GSK 205801) A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants Paris NICOLAS GIRARD
Appareil pulmonaire LUMINOSITY (M14-239) Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer Paris NICOLAS GIRARD